## ALL: The Allstate Corporation - XLF: Financial Services

### Executive Summary

VALUE thesis: PEG 1.24 indicates fundamental undervaluation. Quality metrics strong (ROE 34%). Consistent execution (4/4 quarters beat estimates). Caution: momentum weakening (-4.9% MRS).

- **Horizon:** 20-60 days (position)
- **Risk Profile:** Lower - fundamental undervaluation
- **Stop Type:** Fixed 2xATR ($199.23)
- **If Wrong:** Exit if fundamentals deteriorate or stop hit
- **Invalidation:** PEG > 1.5 or earnings miss

### News

- **Articles:** 10
- **Sentiment:** Neutral (Bullish: 0, Bearish: 0)

**1. Allstate (ALL) president exercises $62.32 options, sells stock at ~$215 in 10b5-1 trades**
- Source: Stock Titan | 20251202T040907 | Somewhat-Bearish | Relevance: 100%
- Suren Gupta, President of Enterprise Solutions at The Allstate Corporation, exercised employee stock options to purchase 4,536 shares of Allstate common stock at $62.32 per share across two dates in late November 2025. Concurrently, he sold the same number of shares on the open market at weighted average prices of approximately $215, all in accordance with a Rule 10b5-1(c) trading plan established on June 9, 2025. After these transactions, Gupta directly beneficially owns 100,646 Allstate shares and retains 19,593 employee stock options.

**2. Allstate (NYSE: ALL) CEO Thomas J. Wilson reports open-market stock sales**
- Source: Stock Titan | 20251204T040907 | Somewhat-Bearish | Relevance: 100%
- Allstate Corporation's Chairman, President, and CEO Thomas J. Wilson reported open-market sales of company stock on December 1, 2025. He sold a total of 16,807 shares in two transactions, carried out under a Rule 10b5-1 trading plan adopted in June 2025. Following these sales, Wilson directly holds 144,812.491 shares and has additional indirect ownership through various trusts and plans.

**3. Allstate Car Insurance Review (2025)**
- Source: Insurify | 20251204T190758 | Neutral | Relevance: 100%
- This detailed review of Allstate Car Insurance highlights its position as the fourth-largest car insurance company in the U.S. It covers customer feedback, industry ratings, comparisons with competitors, coverage options, and the claims process. While Allstate offers competitive rates and a superior financial strength rating, customer satisfaction and claims handling receive mixed reviews.

**4. How to Cancel Your Allstate Auto Insurance Policy in 5 Easy Steps (2025)**
- Source: Insurify | 20251202T090750 | Neutral | Relevance: 100%
- This article outlines a five-step process for canceling an Allstate auto insurance policy. It emphasizes the importance of comparing new quotes and securing a new policy before canceling with Allstate to avoid a coverage lapse, as Allstate does not offer online cancellations and requires direct contact with customer service or an agent. The guide also details how to track potential refunds after cancellation.

**5. Korea Investment CORP Sells 58,400 Shares of Aptiv PLC $APTV**
- Source: MarketBeat | 20251203T113623 | Neutral | Relevance: 71%
- Korea Investment CORP reduced its stake in Aptiv PLC by 32.3% in the second quarter, selling 58,400 shares and now owning 122,228 shares valued at $8.34 million. Despite the institutional selling, Wall Street analysts maintain a "Moderate Buy" consensus with an average price target of $95.42. Aptiv also reported strong quarterly earnings, beating estimates with $2.17 EPS and $5.21 billion in revenue, and provided optimistic FY2025 guidance.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 6, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-11-26 | Roth Capital | $240 | $230 | +4% |
| 2025-11-11 | Keefe, Bruyette | $250 | $246 | +2% |
| 2025-11-10 | UBS | $255 | $250 | +2% |
| 2025-11-07 | Wells Fargo | $216 | $202 | +7% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-11-26 | Roth Capital | main | Buy |
| 2025-11-11 | Keefe, Bruyette | main | Outperform |
| 2025-11-10 | UBS | main | Buy |
| 2025-11-07 | Wells Fargo | main | Equal-Weight |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 8 ($0.16M) |
| Sells | 13 ($14.04M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 41.8% |
| Smart Money | **BEARISH** |
| Net Flow | 0.0% |
| Buying/Selling | 2 / 8 |

**Top Holders:**
- Vanguard Group Inc: 12.7% (-0.3%)
- Blackrock Inc.: 8.5% (-1.0%)
- Price (T.Rowe) Assoc: 4.9% (-17.0%)
- State Street Corpora: 4.5% (+0.7%)
- Geode Capital Manage: 2.7% (+3.3%)

### Key Risks

1. Momentum deterioration: MRS_20 falling (-4.9% 5d) with bearish MACD, trend may be turning.
2. Heavy insider selling: $14M sold (13 transactions in 90 days).
3. Market regime shift could impact momentum names disproportionately.

### Catalysts

- Analyst target momentum: 6 raises (avg +4%) could attract flows.
- Broader market risk-on sentiment could lift quality names.

### Fundamentals

PEG ratio 1.24 suggests fair value with growth premium. Quality metrics strong (ROE 34%). Balance sheet: strong liquidity (30938000000.0x), $3.2B free cash flow. Insider selling cluster ($14.0M in 90 days), potential headwind. Institutional flow bearish (8 selling vs 2 buying).

| Metric | Value |
|--------|-------|
| Market Cap | $54.8B |
| Beta | 0.25 |
| 52W Range | $176.00 - $215.89 |
| Short Interest | 1.7% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 1.24 |
| Forward P/E | 8.6 |
| Current P/E | 7.1 |
| YoY Growth | -17.1% |
| EPS Direction | RISING |

### Technicals

MRS_20 deteriorating from 1.8% to -3.1% (-4.9% in 5 days), indicating relative weakness vs NASDAQ. Below STRENGTH zone by 7.1pp (needs >4.0% for momentum thesis). Underperforming sector by 3.1pp, stock-specific weakness. Long-term uptrend intact (above SMA200 at 1.02x) but short-term weakness (below SMA20). MACD histogram bearish (-0.64), momentum weakening. RSI neutral at 48. OFD pattern: -MUN (Resistance).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | -3.13% (CS: 21) | Weak |
| RSI_14 | 48.3 | Neutral |
| MACD Histogram | -0.64 | Bearish |
| vs SMA20 | 0.986x | Below |
| vs SMA50 | 1.009x | Above |
| vs SMA200 | 1.024x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** VALUE

### Trade Setup

- **Entry:** $206.37
- **Stop Loss:** $199.23 (3.5% risk)
- **Target:** $220.65 (R:R method)
- **Risk/Reward:** 2.00:1
- **Target Reasoning:** VALUE thesis targets 2.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 140
- **Position Value:** $28,891.80
- **Portfolio %:** 28.89%
- **Risk Dollars:** $1,000.00
- **Risk Per Trade:** 1.00%
- **Modifiers:** L1 100% | L2 100% | Combined 1.00x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.00x |
| L2 Sector | NEUTRAL (Zone E) | 1.00x |

*NORMAL regime with moderate risk appetite and mixed signals. VIX at 15.78 indicates calm conditions but breadth at 53% suggests narrow participation. Fed policy remains neutral with 42 days to next meeting, supporting steady positioning with sector selectivity.*

### Earnings

**Next:** 2026-02-04 (Est: $8.25)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $7.54 | $11.17 | +48.1% |
| 2025Q2 | $3.26 | $5.94 | +82.4% |
| 2025Q1 | $2.53 | $3.53 | +39.3% |
| 2024Q4 | $6.28 | $7.67 | +22.1% |

---
*RULE-based L3 | 2026-01-06 16:36 | MRS_20*